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Syphilis diagnosis and treatment during antenatal care: 
the potential catalytic impact of the dual HIV and syphilis 
rapid diagnostic test
An estimated 355 000 adverse pregnancy outcomes 
occur annually due to syphilis,1 two-thirds of which 
result in stillbirth or neonatal death.2 WHO launched 
the Elimination of Mother-to-Child Transmission of 
HIV and Syphilis initiative in 2014.3 However, antenatal 
syphilis screening and treatment rates remain low 
across sub-Saharan Africa and parts of Asia,4 particularly 
compared with progress made to reduce new HIV 
infections among infants, which have declined from 
270 000 in 2010 to 180 000 in 2017.5
Reducing the difference between HIV and syphilis 
antenatal screening rates would lead to major health 
gains. For instance, in many countries, up to 95% of 
women are tested for HIV during antenatal care,6 but less 
than 50% are tested for syphilis7 (figure; appendix).
This gap represents an opportunity to leverage 
existing antenatal care platforms and technologies 
to better diagnose and treat maternal syphilis. In 
2015, the first dual HIV and syphilis rapid diagnostic 
test received WHO prequalification12 on the basis 
of laboratory assessment, with a second test receiving 
prequalification status in June, 2019.13 Field studies 
show optimal sensitivity (98–100%) and specificity 
(97–100%) for HIV diagnosis and good sensitivity 
(89–100%) and specificity (91–100%) for syphilis.14 
Scale up of dual HIV and syphilis rapid diagnostic 
tests could close the antenatal care syphilis testing 
gap, providing an opportunity to deliver treatment 
with injectable benzathine benzylpenicillin during 
the same visit. Successful implementation of dual 
HIV and syphilis rapid diagnostic tests in antenatal 
care would increase syphilis screening rates to match 
those of HIV in countries such as India where antenatal 
care syphilis testing rates would increase by 195%, 
by 119% in Uganda, and by 117% in Nigeria, without 
affecting HIV-testing rates.
Policies, guidelines, advocacy tools, implementation 
plans, screening and diagnostic tests, and effective 
treatment for syphilis are available.14–16 So why does this 
HIV and syphilis antenatal care testing gap exist?
Figure: Testing coverage for HIV and syphilis in pregnant women who visit antenatal care in selected countries (2016–18)
Values are based on syphilis testing rates during antenatal care,7,8 HIV testing rates during antenatal care,6,9 syphilis prevalence,7,10,11 and HIV prevalence.6 *Women aged 
15–49 years. †Antenatal care attendees.
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In 2018, we delivered a series of maternal syphilis 
workshops with maternal and child health programmes 
from 25 African countries to identify reasons for the 
testing gap and opportunities to increase syphilis 
screening in pregnancy. We identified poor awareness and 
political will as contributors to low country application 
of WHO antenatal care syphilis screening guidelines in 
the region. In this regard, neither national governments 
nor donors appear to have identified congenital syphilis 
prevention as a public health priority and few women 
knew of the effect of syphilis in pregnancy. Funding for 
the purchase of syphilis test kits and benzathine penicillin 
primarily comes from national ministries of health 
budgets, where prioritisation of syphilis control is low. In 
addition, donor support is minimal.
Congenital syphilis often falls into the fissures 
between sexually transmitted infections (STI), maternal 
and child health, and reproductive health programmes, 
despite WHO advocacy for service integration as part 
of universal health coverage.17 For example, some HIV 
programme managers regarded adding syphilis to 
prevention of mother-to-child transmission (PMTCT) 
programmes as complicating the process towards 
elimination of mother to child transmission of HIV.
The level of investment in syphilis diagnosis 
and treatment is telling when compared with the 
advocacy, procurement, supply chain, and training 
systems associated with national HIV programmes. 
Workshop participants repeatedly described restrictive 
procurement practices, incomplete demand forecasts, 
inefficient distribution of syphilis tests, shortages 
or stockouts of benzathine penicillin, and missed 
opportunities to leverage health-care worker training.
Integration of maternal syphilis screening and 
treatment into HIV PMTCT programmes is logical. During 
the workshops, countries developed national roadmaps 
for the adoption of new testing algorithms including 
HIV and syphilis rapid diagnostic tests, forecasting and 
procurement of test kits, quality assurance, training, 
and increasing community awareness of syphilis and 
its association with stillbirth prevention. Subsequently, 
many countries, with donor and partner support, 
have commenced activities to identify reliable and 
predictable sources of additional funding to leverage and 
supplement existing HIV PMTCT programmes to include 
dual HIV and syphilis rapid diagnostic tests and ensure 
benzathine penicillin commodity security.
Countries such as Uganda, Kenya, and Nigeria18 reported 
they have already updated their testing algorithm to 
include the dual HIV and syphilis rapid diagnostic test as 
the first test for pregnant women attending antenatal 
care. Several other countries are following suit and 
workshop participants from remaining countries have 
indicated high levels of interest in emulating the process.
Multiplex testing technologies now offer the opportunity 
to immediately close the syphilis HIV testing gap among 
pregnant women. Integrating maternal syphilis screening 
and treatment into HIV PMTCT programmes is a feasible, 
so-called best buy scenario for global health investments, 
is less costly, and results in the fewest adverse pregnancy 
outcomes compared with other testing algorithms.19,20 
Dual HIV and syphilis rapid diagnostic tests have shown a 
high overall diagnostic accuracy for HIV, a high specificity 
for syphilis diagnosis in antenatal clinic settings and are 
rated as highly acceptable and feasible.21
Using the antenatal care platform for diagnosis of 
both maternal HIV and syphilis infections using a single 
rapid diagnostic test is a simple intervention that could 
rapidly be brought to scale in high-burden countries. 
This scenario is a test case for WHO’s people-centred 
integrated service delivery systems. The incremental 
cost is small, but the potential gains—prevention of 
stillbirth, preterm birth, neonatal death, and long-term 
disability of children—are enormous.
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